Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb

Award Number: U01DA037593
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2018

Group Awards By:

View Award Description

Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb - ¿ DESCRIPTION (provided by applicant): Methamphetamine (METH) abuse causes serious medical, social, and economic harm in the USA and the world. However, to date, no medications are approved to treat METH addiction. The primary goal of this translational project is to conduct safety studies of a new medicine for METH addiction, a novel anti- METH monoclonal antibody (mAb) called ch-mAb7F9, to support the initiation of a first clinical study in METH users. Results from a Phase 1a study of ch-mAb7F9 in non-METH-using healthy subjects indicate that the antibody is safe for administration in humans. Ch-mAb7F9 was created to selectively and quickly bind METH in the blood and prevent it from entering the brain and other tissues where it causes multiple health problems, including addiction. By so doing, anti-METH ch-mAb7F9 will transform the clinical treatment of addiction by providing the first medication that can reduce METH's reinforcing properties for prolonged periods of time. There is a high rate of recidivism associated with METH use. By using a long-acting antibody antagonist to provide around-the-clock protection from METH effects, patients will be much less vulnerable to relapse to METH use and thereby have significantly improved chances for recovery. Anti-drug mAb medications have major advantages for addiction therapy since steady-state concentrations and precise control of dosing are readily achievable even in immune compromised patients, and because they will not interact with other medicines. Furthermore, mAb medications are safe for most patient populations. For the research and testing program, ch-mAb7F9 will be tested in rats for safety in combination with high, binge-like doses of METH. Additionally, METH self-administration studies in rats will be performed to answer specific questions from the FDA concerning the motivation and ability of users to overcome the antibody's stimulant blocking effects. A highly experienced, trans disciplinary academic and industry team will accomplish the following Specific Aims: 1) complete essential regulatory work in preparation for a Phase 1b study; 2) manufacture ch-mAb7F9 for necessary nonclinical and future clinical studies, 3) conduct nonclinical testing to determine safety of the interaction between ch-mAb7F9 and METH in rats, and 4) test ch-mAb7F9 in METH self-administration studies to examine the motivational aspect of drug use. These studies are necessary to prepare for a Phase 1b study in METH users that will be crucial for identifying factors that determine optimal human dosing regimens and will allow for the effective design of future clinical studies where ch-mAb7F9 efficacy is the primary endpoint. The therapeutic vision is that this medication, which can be used to initiate and continue pharmacologic treatment, will be used in combination with high quality behavioral modification programs to dramatically improve patient outcomes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = -$50,478 )
2019	2017	INTERVEXION THERAPEUTICS, LLC.	4301 W MARKHAM #831	LITTLE ROCK	AR	72205	PULASKI	USA	Drug Use and Addiction Research Programs	000	3	10/27/2018	SUPPLEMENT FOR EXPANSION	-$50,478
														Subtotal = -$50,478

Issue Date FY: 2017 ( Subtotal = $194,975 )
2017	2017	INTERVEXION THERAPEUTICS, LLC.	4301 W MARKHAM #831	LITTLE ROCK	AR	72205	PULASKI	USA	Drug Use and Addiction Research Programs	000	3	2/21/2017	SUPPLEMENT FOR EXPANSION	$194,975
														Subtotal = $194,975

Issue Date FY: 2016 ( Subtotal = $2,085,133 )
2016	2016	INTERVEXION THERAPEUTICS LLC	4301 WEST MARKHAM STREET	LITTLE ROCK	AR	72205	PULASKI	USA	Drug Use and Addiction Research Programs	000	3	6/3/2016	NON-COMPETING CONTINUATION	$2,085,133
														Subtotal = $2,085,133

Issue Date FY: 2015 ( Subtotal = $1,594,873 )
2015	2015	INTERVEXION THERAPEUTICS LLC	4301 WEST MARKHAM STREET	LITTLE ROCK	AR	72205	PULASKI	USA	Drug Use and Addiction Research Programs	000	2	7/24/2015	NON-COMPETING CONTINUATION	$1,594,873
														Subtotal = $1,594,873

Issue Date FY: 2014 ( Subtotal = $1,287,478 )
2014	2014	INTERVEXION THERAPEUTICS LLC	4301 WEST MARKHAM STREET	LITTLE ROCK	AR	72205	PULASKI	USA	Drug Use and Addiction Research Programs	000	1	9/11/2014	NEW	$1,287,478
														Subtotal = $1,287,478

Grand Total All Awards = $5,111,981

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb

Award Number: U01DA037593

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer